As part of FDA’s proposed biosimilar naming convention, most biologics and biosimilars will have a suffix added to their product’s nonproprietary name that each sponsor must request.
The request would be made either during the IND phase or via a prior-approval labeling supplement if the product has been approved.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?